Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter. Bravaccini S, Ravaioli S, Tumedei MM, Rocca A, et al. Clin Cancer Res 2020;26:3892-3893.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bravaccini S, Ravaioli S, Tumedei MM, Rocca A, et al. Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter. Clin Cancer Res 2020;26:3892-3893.
PMID: 32669274